Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Conditions:   Genetic Disorder;   Noonan SyndromeIntervention:   Drug: somatropinSponsor:   Novo Nordisk A/SActive, not recruiting - verified October 2014

Source: ClinicalTrials.gov - August 22, 2013 Category: Research Source Type: clinical trials